Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Loqtorzi Market Growth Potential: How Will Market Size Shift Through 2030?
Historically, the observed growth was driven by several factors, including the increasing rates of NPC diagnosis in endemic regions, significant advancements in immunotherapy research, the initial success seen in PD-1 blockade trials, a rise in oncology research funding, and the expansion of specialty cancer centers.
Expected market expansion over the forecast horizon is driven by a rise in worldwide approvals for immunotherapy medications, increased capital allocation towards therapies for rare cancers, broader availability of oncology biologics, wider application of combined immunotherapy approaches, and ongoing advancements in immune system modulation treatments. Significant trends for the forecast period feature greater integration of PD-1 inhibitors in treating uncommon cancers, a heightened emphasis on addressing nasopharyngeal carcinoma, the broadening of immuno-oncology drug development programs, an uptick in the utilization of immune checkpoint blockade treatments, and increased worldwide clinical investigation efforts.
Get A Free Sample Report With In-Depth Market Insights:
Loqtorzi Market Industry Drivers: What’s Behind The Revenue Growth?
An anticipated increase in the incidence of nasopharyngeal carcinoma is set to drive the expansion of the loqtorzi market in the future. Nasopharyngeal carcinoma, a form of cancer impacting the nasopharynx, exhibits a strong association with Epstein-Barr virus infection, where prompt detection is crucial for successful treatment results. This escalating prevalence of nasopharyngeal carcinoma stems from various elements, including heightened exposure to the Epstein-Barr virus, inherited genetic susceptibilities, environmental influences like tobacco and alcohol consumption, and nutritional practices, especially the intake of salted and preserved food items. Loqtorzi (toripalimab) aids nasopharyngeal carcinoma (NPC) patients by strengthening the immune system’s capacity to target cancerous cells via the suppression of the PD-1 pathway, providing an innovative therapeutic alternative for individuals with recurrent or metastatic NPC, either when combined with chemotherapy or as a single agent following disease advancement. As an illustration, in October 2024, data from Cancer Research UK, a registered charity located in the UK, indicated that head and neck cancer occurrences in the UK are projected to rise by 3% when contrasting the 2023–2025 period with 2038–2040. Consequently, the increasing prevalence of nasopharyngeal carcinoma is propelling the expansion of the loqtorzi market.
Loqtorzi Market Segment Analysis Spotlighting Growth Areas
The loqtorzi market covered in this report is segmented –
1) By Formulation: Injectable Formulation (intravenous), Lyophilized Powder For Reconstitution
2) By Indication: Treatment Of Small Cell Lung Cancer (SCLC), Treatment Of Other Solid Tumors
3) By Patient Demographics: Adult Patients, Geriatric Patients, Pediatric Patients
4) By Distribution Channel: Direct Sales, Wholesalers and Distributors, Retail Pharmacies, Online Pharmacies
5) By End User: Hospitals, Oncology Clinics, Specialty Pharmacies, Research Institutions
#Loqtorzi Market Growth Trends: What’s Shaping The Future Outlook?
A significant trend in the Loqtorzi market centers on the development of biosimilars to expand product portfolios and offer more cost-effective treatment alternatives to biologic therapies. Biosimilars are biologic products that share a high degree of similarity with an approved reference product, showing no clinically meaningful differences in their safety or effectiveness. These products offer a budget-friendly substitute for expensive biologic drugs once the original product’s patent protection expires. As an illustration, in November 2024, Dr. Reddy’s Laboratories, an India-based pharmaceutical company, launched Zytorvi in India, a biosimilar of Coherus BioSciences’ (CHRS) Loqtorzi (toripalimab). This drug is indicated for the treatment of adults suffering from recurrent or metastatic nasopharyngeal carcinoma (RM-NPC), a rare cancer type. Loqtorzi itself was FDA-approved in October 2023 for the first-line treatment of RM-NPC when used in combination with cisplatin and gemcitabine, and also as a monotherapy for patients whose disease has progressed after platinum-based chemotherapy. It holds the distinction of being the sole FDA-approved immuno-oncology drug for this particular indication.
Loqtorzi Market Leading Companies: Who Holds The Strongest Market Presence?
Major companies operating in the loqtorzi market are Coherus BioSciences Inc., Shanghai Junshi Biosciences Co. Ltd.
View The Full Loqtorzi Market Report:
Loqtorzi Market Regional Outlook: Where Is Opportunity Concentrated?
North America was the largest region in the loqtorzi market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the loqtorzi market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
